Dispatching dysbiosis

MaaT Pharma S.A. is developing autologous fecal transplants for cancer therapy-induced dysbiosis, a condition that affects a large proportion of patients but has no approved treatment. The company expects its products to have longer-lasting effects in the gut than allogeneic fecal transplants, and plans to test its approach in the clinic this year, starting with dysbiosis in leukemia patients receiving chemotherapy.

Dysbiosis results from imbalanced exchanges between the intestinal microbiome and the host caused by